



0590

Patent Docket P1134R2C1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Ashkenazi et al.

Serial No.: 09/894,924

Filed: June 28, 2001

For: DcR3 Polypeptide, A TNFR Homolog

Group Art Unit: To be assigned

Examiner: To be assigned

**CERTIFICATE OF EXPRESS MAILING**  
I hereby certify that this correspondence is being deposited with the United States Postal Service via Express Mail service Post Office to Addressee, No. EL599583833US in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

August 13, 2001  
*Diane L. Marschang*  
Diane L. Marschang

TRANSMITTAL

Assistant Commissioner of Patents  
Washington, D.C. 20231

RECEIVED

DEC 06 2001

Sir:

Transmitted herewith is a Preliminary Amendment in the above-identified application.

TECH CENTER 1600/2900

The fee has been calculated as shown below.

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	20	-	20	0	x 18 =	\$0.00
Independent	2	-	3	0	x 78 =	\$0.00
Multiple dependent claim(s), if any					+ 260 =	\$0.00
Total Fee Calculation						\$0.00

  X    
\_\_\_\_\_  
\_\_\_\_\_

No additional fee is required.

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$0.00. A duplicate copy of this transmittal is enclosed.  
Petition for Extension of Time is enclosed.

  X   The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this sheet is enclosed.

Respectfully submitted,  
GENENTECH, INC.


Date: August 13, 2001

By *Diane L. Marschang*  
Diane L. Marschang  
Reg. No. 35,600  
Telephone No. (650) 225-5416.



09157

PATENT TRADEMARK OFFICE



# 4/8  
RB  
12/11/01

Patent Docket P1134R2C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>In re Application of Avi J. Ashkenazi et al. Serial No.: 09/894,924 Filed: June 28, 2001 For: DcR3 Polypeptide, A TNFR Homolog</p>	<p>Group Art Unit: To be assigned Examiner: To be assigned</p> <p><b>CERTIFICATE OF Express MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service via Express Mail, Express Mail No. EL599583833US in an envelope to: Assistant Commissioner of Patents, Washington, D.C. 20231 on August <sup>13</sup> 2001 <i>Diane L. Marschang</i> Diane L. Marschang</p>
---	--

**PRELIMINARY AMENDMENT**

**RECEIVED**

DEC 6 2001

Assistant Commissioner of Patents  
Washington, D.C. 20231

**TECH CENTER 1600/2900**

SIR:

The present Continuation Application was filed on June 28, 2001. Entry of the following Preliminary Amendment is respectfully requested prior to examination on the merits.

**In the specification:**

On pages 2-3, in the paragraph on lines 31-42 and lines 1-6, the text has been amended to read:

8' --Induction of various cellular responses mediated by such TNF family cytokines is believed to be initiated by their binding to specific cell receptors. Two distinct TNF receptors of approximately 55-kDa (TNFR1) and 75-kDa (TNFR2) have been identified [Hohmann et al., J. Biol. Chem., 264:14927-14934 (1989); Brockhaus et al., Proc. Natl. Acad. Sci., 87:3127-3131 (1990); EP 417,563, published March 20, 1991] and human and mouse cDNAs corresponding to both receptor types have been isolated and characterized [Loetscher et al., Cell, 61:351 (1990); Schall et al., Cell, 61:361 (1990);